- Multivariate analysis identified the following as independent risk factors for hospital mortality 23:
- Analysis of secondary outcomes showed patients who received empirical antifungal treatment within 12 hours (n=9) had statistically shorter 23
-
- Delay in antifungal treatment (>12 hours)a (P=0.018)
- Greater APACHE II score (P<0.001)
- Prior antibiotic treatment (P=0.028)
-
- Duration of intensive-care stay
- Duration of mechanical ventilation
a
Defined as the time when the first blood sample for culture positive for fungi was drawn to the time when antifungal treatment was first administered to the patient. 23
References
2.
Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol. 2005;43:235–243.
3.
Vazquez JA, Dembry LM, Sanchez V, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol. 1998;36:421–426.
4.
Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996;9:499–511.
5.
Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358–4366.
23.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–3645.
